Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 4/20 | 0.36 |
| ▸ | MMP14 | P50281 | 4/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP17 | Q9ULZ9 | 2/20 | 0.34 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609772 | 0.90 | GRM2 (0.47) | PKMALDH1A1GRM2 | |
| SCHEMBL29161590 | 0.87 | PKM (0.40) | PKMALDH1A1GRM2DRD2DRD3 | |
| SCHEMBL22824347 | 0.81 | CNR2 (0.46) | PKMALDH1A1GRM2DRD2DRD3 | |
| SCHEMBL15118488 | 0.79 | PKM (0.43) | PKMALDH1A1DRD2DRD3MMP8 | |
| SCHEMBL13432029 | 0.79 | PKM (0.47) | PKMDRD2DRD3MMP8MMP14 | |
| SCHEMBL17618306 | 0.79 | ALDH1A1 (0.33) | ALDH1A1GRM2MAPT | |
| SCHEMBL1345895 | 0.79 | PKM (0.40) | PKMALDH1A1GRM2DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3389277 | 0.78 | PKM (0.46) | PKMDRD2DRD3MMP8MMP14 | |
| SCHEMBL1130229 | 0.78 | PKM (0.46) | PKMDRD2DRD3MMP8MMP14 | |
| SCHEMBL29161579 | 0.78 | PKM (0.42) | PKMDRD2DRD3MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | KIT, CMA1, C3AR1 | PKM 703/4885ALDH1A1 491/4885GRM2 3658/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | PKM 703/4885ALDH1A1 491/4885GRM2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.